Photo of Jo Jones
D Texas House · District 147 On the 2026 ballot

Rep. Jo Jones

Compare
Total votes
5,630
all sessions
Attendance
94%
355 missed
Near the chamber average
With party
94%
of cast votes
Near the chamber average
Bipartisan score
3%
crosses aisle rarely
Near the chamber average
Sponsored
249
bills & resolutions
Lower than 80% of chamber peers
Committees
3
assignments
5,630 roll-call votes

Voting record

Yea
4,518
voted in favor
Nay
771
voted against
Absent
355
missed votes
Total cast
5,630
across all sessions
Crossed party
309
votes against own party
This page
5,630
matching current filters
Bill
Description
Vote
Result
Tally
Date
HB 4506
Relating to electronic delivery of notice for certain municipal zoning changes.
Yea
Passed
139–0
May 12, 2025
SB 842
Relating to immunity for ringside physicians assigned to combative sports events.
Yea
Passed
141–1
May 12, 2025
HB 3892
Relating to county regulation related to infrastructure planning for subdivisions and county authority to regulate building and set-back lines.
Nay
Passed
80–54
May 12, 2025
HB 4936
Relating to a study by the Texas Economic Development and Tourism Office regarding the creation of the Department of Marketing Services.
Yea
Passed
116–25
May 12, 2025
HB 2434
Relating to the purchase of service credit by certain members of the Employees Retirement System of Texas.
Yea
Passed
145–1
May 12, 2025
HB 3722
Relating to the height of a structure near certain airspace designated for use by Department of Defense contractors.
Nay
Passed
85–54
May 12, 2025
HB 1896
Relating to a mental health leave policy for certain public safety employees.
Yea
Passed
126–11
May 12, 2025
HB 3221
Relating to certain employer contributions to the Teacher Retirement System of Texas. Against party
Nay
Passed
122–18
May 12, 2025
SB 2550
Relating to an exemption of the transfer of certain rights in water from certain disclosure requirements applicable to the transfer of certain interests in real property.
Yea
Passed
126–17
May 12, 2025
SB 2308
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Yea
Passed
141–1
May 12, 2025
Showing 1,841 to 1,850 of 5,630 votes